Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, Cristina Marti, Manuel Cobo, Vanesa Gutiérrez, Manuel Dómine, Jose Fuentes, Margarita Majem, Javier de Castro, Juan Felipe Cordoba, Maria Pilar Diz, Dolores Isla, Emilio Esteban, Enric Carcereny, Laia Vila, Alberto Moreno-Vega, Silverio Ros, Amaia Moreno, Francisco Javier Garcia, Gerardo Huidobro, Carlos Aguado, Victor Cebey-Lopez, Javier Valdivia, Ramon Palmero, Pilar Lianes, Marta Lopez-Brea, Oscar Juan Vidal, Mariano Provencio, Edurne Arriola, Javier Baena, Mercedes Herrera, Helena Bote, Magdalena Molero, Vera Adradas, Santiago Ponce-Aix, Angel Nuñez-Buiza, Álvaro Ucero, Susana Hernandez, Fernando Lopez-Rios, Esther Conde, Luis Paz-Ares, Jon Zugazagoitia
BACKGROUND: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small-cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC. PATIENTS AND METHODS: We analyzed tumor samples from 58 ES-SCLC patients enrolled in two multicenter single-arm phase IIIb studies evaluating front-line chemoimmunotherapy in Spain: n=32 from the IMfirst trial, and n=26 from the CANTABRICO trial...
April 17, 2024: Clinical Cancer Research
#2
JOURNAL ARTICLE
Jennifer A Collister, Xiaonan Liu, Thomas J Littlejohns, Jack Cuzick, Lei Clifton, David J Hunter
BACKGROUND: Previous studies have demonstrated that incorporating a polygenic risk score (PRS) to existing risk prediction models for breast cancer improves model fit, but to determine its clinical utility the impact on risk categorisation needs to be established. We add a PRS to two well-established models and quantify the difference in classification using the net reclassification improvement (NRI). METHODS: We analysed data from 126,490 post-menopausal women of "White British" ancestry, aged 40-69 years at baseline from the UK Biobank prospective cohort...
April 17, 2024: Cancer Epidemiology, Biomarkers & Prevention
#3
JOURNAL ARTICLE
Alec Rhodes, Stephanie Moulton, Cäzilia Loibl, Donald Haurin, Joshua Joseph
OBJECTIVE: The medical diagnosis of a disease is common in older age and can carry significant financial costs. For many older adults, equity in a home is their primary component of wealth; however, housing wealth is illiquid. We analyze the relationship between the liquidation of housing wealth through mortgage borrowing on older homeowners' ability to successfully control a disease. METHODS: We use data on homeowners age 65 and older from the 1998-2016 waves of the Health and Retirement Study (N=3,457)...
April 17, 2024: Journals of Gerontology. Series B, Psychological Sciences and Social Sciences
#4
JOURNAL ARTICLE
Birgit S Geurts, Laurien J Zeverijn, Lindsay V M Leek, Jade M van Berge Henegouwen, Louisa R Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Joris van de Haar, Annemiek van Ommen-Nijhof, Marleen Kok, Paul Roepman, Anne M L Jansen, Wendy W J de Leng, Maja J A de Jonge, Ann Hoeben, Carla M L van Herpen, Hans M Westgeest, Lodewyk F A Wessels, Henk M W Verheul, Hans Gelderblom, Emile E Voest
PURPOSE: To evaluate efficacy of pembrolizumab across multiple cancer types harboring different levels of Whole-Genome Sequencing (WGS)-based tumor mutational load (TML; total of non-synonymous mutations across the genome) in patients included in the Drug Rediscovery Protocol (NCT02925234). PATIENTS AND METHODS: Patients with solid, treatment-refractory, microsatellite-stable tumors were enrolled in cohort A: breast cancer TML 140-290, cohort B: tumor-agnostic cohort TML 140-290, and cohort C: tumor-agnostic cohort TML >290...
April 17, 2024: Clinical Cancer Research
#5
JOURNAL ARTICLE
Tinaye Mutetwa, Yuxin Liu, Richard Silvera, Michelle Evans, Michael Yurich, Joseph Tripodi, Issa Leonard, Jane Houldsworth, Zeynep Gümüş, Anne M Bowcock, Keith Sigel, Michael Gaisa, Paz Polak
BACKGROUND: People living with HIV (PLWH) have substantially increased incidence of anal precancer and cancer. There are very little data regarding genomic disturbances in anal precancers among PLWH. Here, we identified specific chromosomal variants in anal squamous intraepithelial lesions. METHODS: We collected 63 anal biopsy specimens (27 low-grade intraepithelial lesions [LSIL] and 36 high-grade intraepithelial lesions [HSIL]) from PLWH obtained as part of anal cancer screening in our NYC-based health system...
April 15, 2024: Journal of Acquired Immune Deficiency Syndromes: JAIDS
#6
REVIEW
Emily J Patterson, Alistair D Bounds, Siegfried K Wagner, Richard Kadri-Langford, Robin Taylor, Dan Daly
Chronic, non-communicable diseases present a major barrier to living a long and healthy life. In many cases, early diagnosis can facilitate prevention, monitoring, and treatment efforts, improving patient outcomes. There is therefore a critical need to make screening techniques as accessible, unintimidating, and cost-effective as possible. The association between ocular biomarkers and systemic health and disease (oculomics) presents an attractive opportunity for detection of systemic diseases, as ophthalmic techniques are often relatively low-cost, fast, and non-invasive...
April 17, 2024: Ophthalmology and Therapy
#7
JOURNAL ARTICLE
Ayse Nilgun Kul, Bahar Ozturk Kurt
Trace elements are essential micronutrients for the human body. Their roles are indispensable, as they are involved in a wide range of vital biological processes. In this study, we aimed to evaluate alterations in trace elements in the blood and bone marrow serum of patients with newly diagnosed multiple myeloma (NMM). The levels of zinc (Zn), copper (Cu), iron (Fe), manganese (Mn), magnesium (Mg), selenium (Se), arsenic (As), boron (B), nickel (Ni), silicon (Si) and chromium (Cr) were analyzed in the venous blood samples of the patient group comprising 70 patients with NMM (41 males and 29 females) and compared to those in the control group comprising 30 individuals (18 males and 12 females)...
April 17, 2024: Clinical and Experimental Medicine
#8
REVIEW
Patrick J Bradley, Göran Stenman, Lester D R Thompson, Alena Skálová, Roderick H W Simpson, Pieter J Slootweg, Alessandro Franchi, Nina Zidar, Alfons Nadal, Henrik Hellquist, Michelle D Williams, Ilmo Leivo, Abbas Agaimy, Alfio Ferlito
Primary squamous cell carcinoma of the parotid gland (pSCCP) has long been recognized as a separate entity and is included in the WHO classifications of salivary gland tumors. However, it is widely accepted among head and neck pathologists that pSCCP is exceptionally rare. Yet, there are many publications describing series of pSCCP and data from SEER and other cancer register databases indicate erroneously an increasing incidence of pSCCP. Importantly, pSCCP and metastatic (secondary) squamous cell carcinoma to the parotid gland (mSCCP) have nearly identical histological features, and the diagnosis of pSCCP should only be made after the exclusion of mSCCP...
April 17, 2024: Virchows Archiv: An International Journal of Pathology
#9
JOURNAL ARTICLE
Junqiu Liu, Zhaidong Liu, Chunqin Zhao, Yuting Jiao, Baohong Li, Jiaju Shi, Zichao Chen, Zhen Zhang
Exosomal programmed death ligand-1 (ExoPD-L1) is a vital marker of immune activation in the early stages of tumor therapy and it can inhibit anti-tumor immune responses. However, due to the low expression of ExoPD-L1 in cancer cells, it is difficult to perform highly sensitive assays and accurately differentiate cancer sources. Therefore, we constructed a coaxial dual-path electrochemical biosensor for highly accurate identification and detection of ExoPD-L1 from lung cancer based on chemical-biological coaxial nanomaterials and nucleic acid molecular signal amplification strategies...
April 17, 2024: Nanoscale
#10
JOURNAL ARTICLE
Toshiaki Iwase, Evan N Cohen, Hui Gao, Angela Alexander, Megumi Kai, Vivian Chiv, Xiaoping Wang, Savitri Krishnamurthy, Diane Liu, Yu Shen, Kumiko Kida, Alexandre Reuben, Rachel Layman, David Ramirez, Debu Tripathy, Stacy L Moulder, Clinton Yam, Vicente Valero, Bora Lim, James M Reuben, Naoto T Ueno
PURPOSE: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy of maintenance immunotherapy in patients with metastatic HER2-negative inflammatory breast cancer (IBC) and non-IBC triple-negative breast cancer (TNBC) and a biomarker study. PATIENTS AND METHODS: Patients with a complete response (CR), partial response (PR), or stable disease (SD) after at least 3 cycles of chemotherapy for HER2-negative breast cancer received pembrolizumab, regardless of programmed death-ligand 1 expression...
April 17, 2024: Clinical Cancer Research
#11
JOURNAL ARTICLE
Zekang Su, Yali Zhang, Shiyi Hong, Qiaojian Zhang, Zhiqiang Ji, Guiping Hu, Xiaojun Zhu, Fang Yuan, Shanfa Yu, Tianchen Wang, Li Wang, Guang Jia
Exposure to hexavalent chromium damages genetic materials like DNA and chromosomes, further elevating cancer risk, yet research rarely focuses on related immunological mechanisms, which play an important role in the occurrence and development of cancer. We investigated the association between blood chromium (Cr) levels and genetic damage biomarkers as well as the immune regulatory mechanism involved, such as costimulatory molecules, in 120 workers exposed to chromates. Higher blood Cr levels were linearly correlated with higher genetic damage, reflected by urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and blood micronucleus frequency (MNF)...
April 17, 2024: Environmental Science & Technology
#12
JOURNAL ARTICLE
PLK3 is linked with higher tumor stage and unfavorable prognosis in patients with colorectal cancer.
Hai Zeng, Qian Wang, Ying Xiang, Yameng Yang, Xia Tu, Hui He, Shuang Li, Weijia Zhang
Objective: This study intended to explore the relationship of PLK3 with prognosis in patients with colorectal cancer (CRC). Methods: PLK3 positivity was detected by immunohistochemistry in 160 patients with CRC receiving surgical resection. Results: The median tumor PLK3-positive rate was 26.5%. Tumor PLK3-positive rate was related to increased lymph node stage (p = 0.002) and tumor-node-metastasis stage (p < 0.001) of CRC. Tumor PLK3-positive rate ≥30% was related to shortened disease-free survival (p = 0...
April 17, 2024: Biomarkers in Medicine
#13
JOURNAL ARTICLE
Imogen R Walpole, Farzana Y Zaman, Peinan Zhao, Vikki M Marshall, Frank P Lin, David M Thomas, Mark Shackleton, Albert A Antolin, Malaka Ameratunga
PURPOSE: Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. METHODS: Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO-500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature...
April 2024: Clinical and Translational Medicine
#14
JOURNAL ARTICLE
Xiaoyu Liang, Bradley E Aouizerat, Kaku So-Armah, Mardge H Cohen, Vincent C Marconi, Ke Xu, Amy C Justice
Telomere length (TL) is an important indicator of cellular aging. Shorter TL is associated with several age-related diseases including coronary heart disease, heart failure, diabetes, osteoporosis, and cancer. Recently, a DNA methylation-based TL (DNAmTL) estimator has been developed as an alternative method for directly measuring TL. In this study, we examined the association of DNAmTL with cancer prevalence and mortality risk among people with and without HIV in the Veterans Aging Cohort Study Biomarker Cohort (VACS, N = 1917) and Women's Interagency HIV Study Cohort (WIHS, N = 481)...
April 17, 2024: Aging Cell
#15
JOURNAL ARTICLE
Hanping He, Feng Yuan, Ying Li, Guoliang Pi, Hongwei Shi, Yanping Li, Guang Han
BACKGROUND: The role of Forkhead Box D2 (FOXD2) in head and neck squamous cell carcinoma (HNSC) has never been studied. OBJECT: Our object was to explore the role of FOXD2 in HNSC. METHODS: Clinical data for patients with HNSC was obtained from TCGA. Our study examined the atypical expression of FOXD2 in both HNSC and pan-cancer, along with its diagnostic and prognostic implications, as well as the association between FOXD2 expression and clinical characteristics, immune infiltration, immune checkpoint genes, and MSI...
April 16, 2024: Current Computer-aided Drug Design
#16
JOURNAL ARTICLE
Susan Aherne, Mark Donnelly, Éanna J Ryan, Matthew G Davey, Ben Creavin, Erinn McGrath, Aoife McCarthy, Robert Geraghty, David Gibbons, Iris Nagtegaal, Alessandro Lugli, Richard Kirsch, Sean T Martin, Desmond C Winter, Kieran Sheahan
BACKGROUND: Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility of TB assessment in the setting of neoadjuvant treatment. METHODS AND RESULTS: A single-centre, retrospective cohort study was conducted. TB was assessed using the hot-spot International Tumour Budding Consortium (ITBCC) method and classified by the revised ITBCC criteria...
April 17, 2024: Histopathology
#17
JOURNAL ARTICLE
Kamil Nurczyk, Norbert Nowak, Tomasz Orczykowski, Paweł Bojar, Dariusz Duma, Renata Gieroba, Grzegorz Wallner, Tomasz Skoczylas
<b><br>Introduction:</b> Neoadjuvant chemotherapy (NAC) is a part of the current standard of care in a locally advanced gastric adenocarcinoma (GA) and esophagogastric junction adenocarcinoma (EGJA), but only patients with good pathomorphological response (pR) to NAC benefit from prolonged overall survival.</br> <b><br>Aim:</b> The study aims to evaluate ApoA-I and ApoB as candidate pre-treatment biomarkers of pR to NAC in patients with GA and EGJA...
September 20, 2023: Polski Przeglad Chirurgiczny
#18
JOURNAL ARTICLE
Fengnian Zhao, Jinge Zhao, Xinyuan Wei, Yifu Shi, Nanwei Xu, Sha Zhu, Junru Chen, Guangxi Sun, Jindong Dai, Zhipeng Wang, Xingming Zhang, Jiayu Liang, Xu Hu, Haoyang Liu, Junjie Zhao, Zhenhua Liu, Ling Nie, Pengfei Shen, Ni Chen, Hao Zeng
BACKGROUND: KI67 is a well-known biomarker reflecting cell proliferation. We aim to elucidate the predictive role of KI67 in the efficacy of abiraterone for patients with advanced prostate cancer (PCa). METHODS: Clinicopathological data of 152 men with metastatic PCa, who received abiraterone therapy were retrospectively collected. The KI67 positivity was examined by immunohistochemistry using the prostate biopsy specimen. The predictive value of KI67 on the therapeutic efficacy of abiraterone was explored using Kaplan-Meier curve and Cox regression analysis...
April 17, 2024: Prostate
#19
JOURNAL ARTICLE
Zhenyuan Qian, Fang Wu, Guoqing Feng, Wenfa Lin, Xufan Cai, Jianzhang Wu, Kun Ke, Zaiyuan Ye, Guoxi Xu
BACKGROUND: Increased lactate levels and metastasis in tumours are strongly associated with dismal outcomes. But prognostic value of lactate metabolism and transport-related lncRNAs in gastric adenocarcinoma (GA) patients remains unaddressed. METHODS: Gene expression data of GA were provided by The Cancer Genome Atlas. Lactate metabolism and transport-related gene data were accessed from GSEA. LncRNAs related to lactate metabolism and transport were identified by correlation analysis...
April 17, 2024: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
#20
JOURNAL ARTICLE
Samaneh Rezaei, Mohammad Hasan Jafari Najaf Abadi, Mohammad Javad Bazyari, Amin Jalili, Reza Kazemi Oskuee, Seyed Hamid Aghaee-Bakhtiari
OBJECTIVES: MicroRNAs, which are micro-coordinators of gene expression, have been recently investigated as a potential treatment for cancer. The study used computational techniques to identify microRNAs that could target a set of genes simultaneously. Due to their multi-target-directed nature, microRNAs have the potential to impact multiple key pathways and their pathogenic cross-talk. MATERIALS AND METHODS: We identified microRNAs that target a prostate cancer-associated gene set using integrated bioinformatics analyses and experimental validation...
2024: Iranian Journal of Basic Medical Sciences
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
